These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 28618427)

  • 1. Matrix Metalloproteases in Arterial Hypertension and their Trend after Antihypertensive Treatment.
    Hopps E; Lo Presti R; Caimi G
    Kidney Blood Press Res; 2017; 42(2):347-357. PubMed ID: 28618427
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Matrix metalloproteinases: their biological functions and clinical implications.
    Hijova E
    Bratisl Lek Listy; 2005; 106(3):127-32. PubMed ID: 16026148
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Matrix metalloproteases as a pharmacological target in cardiovascular diseases.
    Hopps E; Caimi G
    Eur Rev Med Pharmacol Sci; 2015; 19(14):2583-9. PubMed ID: 26221886
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Matrix metalloproteinases, inflammation and atherosclerosis: therapeutic perspectives.
    Beaudeux JL; Giral P; Bruckert E; Foglietti MJ; Chapman MJ
    Clin Chem Lab Med; 2004 Feb; 42(2):121-31. PubMed ID: 15061349
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Matrix metalloproteinases and their tissue inhibitors in hypertension-related pregnancy complications.
    Karthikeyan VJ; Lane DA; Beevers DG; Lip GY; Blann AD
    J Hum Hypertens; 2013 Feb; 27(2):72-8. PubMed ID: 22418748
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Matrix metalloproteinases and their inhibitors in vascular remodeling and vascular disease.
    Raffetto JD; Khalil RA
    Biochem Pharmacol; 2008 Jan; 75(2):346-59. PubMed ID: 17678629
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interplay of angiotensin II and angiotensin(1-7) in the regulation of matrix metalloproteinases of human cardiocytes.
    Pan CH; Wen CH; Lin CS
    Exp Physiol; 2008 May; 93(5):599-612. PubMed ID: 18296491
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Matrix metalloproteinases and diabetic vascular complications.
    Kadoglou NP; Daskalopoulou SS; Perrea D; Liapis CD
    Angiology; 2005; 56(2):173-89. PubMed ID: 15793607
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of metalloproteinases and tissue inhibitors of metalloproteinases during cardiopulmonary bypass in rats.
    Guenzinger R; Lahm H; Wottke M; Lange R
    ASAIO J; 2012; 58(3):204-11. PubMed ID: 22395114
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Matrix metalloproteinases and their inhibitors in non-neoplastic otorhinolaryngological disease.
    De S; Fenton JE; Jones AS
    J Laryngol Otol; 2005 Jun; 119(6):436-42. PubMed ID: 15992468
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comprehensive evaluation of the effects of enalapril on matrix metalloproteinases levels in hypertension.
    Fontana V; Silva PS; Izidoro-Toledo TC; Biagi C; Oliveira EB; Gerlach RF; Tanus-Santos JE
    Cardiovasc Drugs Ther; 2012 Dec; 26(6):511-9. PubMed ID: 23085896
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Circulating matrix metalloproteinases and their inhibitors in hypertension.
    Fontana V; Silva PS; Gerlach RF; Tanus-Santos JE
    Clin Chim Acta; 2012 Apr; 413(7-8):656-62. PubMed ID: 22245508
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TIMP3 is the primary TIMP to regulate agonist-induced vascular remodelling and hypertension.
    Basu R; Lee J; Morton JS; Takawale A; Fan D; Kandalam V; Wang X; Davidge ST; Kassiri Z
    Cardiovasc Res; 2013 Jun; 98(3):360-71. PubMed ID: 23524300
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Extracellular matrix -- from basic research to clinical significance. An overview with special consideration of matrix metalloproteinases].
    Hamacher S; Matern S; Roeb E
    Dtsch Med Wochenschr; 2004 Sep; 129(38):1976-80. PubMed ID: 15375740
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Matrix metalloproteinases and atherosclerosis. Therapeutic aspects].
    Beaudeux JL; Giral P; Bruckert E; Foglietti MJ; Chapman MJ
    Ann Biol Clin (Paris); 2003; 61(2):147-58. PubMed ID: 12702469
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Extracellular matrix remodelling in human aortic valve disease: the role of matrix metalloproteinases and their tissue inhibitors.
    Fondard O; Detaint D; Iung B; Choqueux C; Adle-Biassette H; Jarraya M; Hvass U; Couetil JP; Henin D; Michel JB; Vahanian A; Jacob MP
    Eur Heart J; 2005 Jul; 26(13):1333-41. PubMed ID: 15827062
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MMPs and TIMPs expression in facial tissue of children with cleft lip and palate.
    Smane-Filipova L; Pilmane M; Akota I
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2016 Dec; 160(4):538-542. PubMed ID: 27876897
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TIMPs as multifacial proteins.
    Lambert E; Dassé E; Haye B; Petitfrère E
    Crit Rev Oncol Hematol; 2004 Mar; 49(3):187-98. PubMed ID: 15036259
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of antiglaucoma drops on MMP and TIMP balance in conjunctival and subconjunctival tissue.
    Ito T; Ohguro H; Mamiya K; Ohguro I; Nakazawa M
    Invest Ophthalmol Vis Sci; 2006 Mar; 47(3):823-30. PubMed ID: 16505013
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Time profiles of the expression of metalloproteinases, tissue inhibitors of metalloproteases, cytokines and collagens in hamsters infected with Opisthorchis viverrini with special reference to peribiliary fibrosis and liver injury.
    Prakobwong S; Pinlaor S; Yongvanit P; Sithithaworn P; Pairojkul C; Hiraku Y
    Int J Parasitol; 2009 Jun; 39(7):825-35. PubMed ID: 19168069
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.